These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 37860991

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Changes in glycogen and glycosaminoglycan levels in hepatocytes of iduronate-2-sulfatase knockout mice before and after recombinant iduronate-2-sulfatase supplementation.
    Lee JH, Choe YH, Kim SJ, Paik KH, Jin DK.
    Yonsei Med J; 2011 Mar; 52(2):263-7. PubMed ID: 21319344
    [Abstract] [Full Text] [Related]

  • 24. Glycosaminoglycan signatures in body fluids of mucopolysaccharidosis type II mouse model under long-term enzyme replacement therapy.
    Maccari F, Rigon L, Mantovani V, Galeotti F, Salvalaio M, D'Avanzo F, Zanetti A, Capitani F, Gabrielli O, Tomanin R, Volpi N.
    J Mol Med (Berl); 2022 Aug; 100(8):1169-1179. PubMed ID: 35816218
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Detection of mucopolysaccharidosis type II by measurement of iduronate-2-sulfatase in dried blood spots and plasma samples.
    Dean CJ, Bockmann MR, Hopwood JJ, Brooks DA, Meikle PJ.
    Clin Chem; 2006 Apr; 52(4):643-9. PubMed ID: 16497940
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Extension of the molecular analysis to the promoter region of the iduronate 2-sulfatase gene reveals genomic alterations in mucopolysaccharidosis type II patients with normal coding sequence.
    Brusius-Facchin AC, Abrahão L, Schwartz IV, Lourenço CM, Santos ES, Zanetti A, Tomanin R, Scarpa M, Giugliani R, Leistner-Segal S.
    Gene; 2013 Sep 10; 526(2):150-4. PubMed ID: 23707223
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
    Whiteman DA, Kimura A.
    Drug Des Devel Ther; 2017 Sep 10; 11():2467-2480. PubMed ID: 28860717
    [Abstract] [Full Text] [Related]

  • 34. Molecular architecture determines brain delivery of a transferrin receptor-targeted lysosomal enzyme.
    Arguello A, Mahon CS, Calvert MEK, Chan D, Dugas JC, Pizzo ME, Thomsen ER, Chau R, Damo LA, Duque J, Fang M, Giese T, Kim DJ, Liang N, Nguyen HN, Solanoy H, Tsogtbaatar B, Ullman JC, Wang J, Dennis MS, Diaz D, Gunasekaran K, Henne KR, Lewcock JW, Sanchez PE, Troyer MD, Harris JM, Scearce-Levie K, Shan L, Watts RJ, Thorne RG, Henry AG, Kariolis MS.
    J Exp Med; 2022 Mar 07; 219(3):. PubMed ID: 35226042
    [Abstract] [Full Text] [Related]

  • 35. The efficacy of intracerebroventricular idursulfase-beta enzyme replacement therapy in mucopolysaccharidosis II murine model: heparan sulfate in cerebrospinal fluid as a clinical biomarker of neuropathology.
    Sohn YB, Ko AR, Seong MR, Lee S, Kim MR, Cho SY, Kim JS, Sakaguchi M, Nakazawa T, Kosuga M, Seo JH, Okuyama T, Jin DK.
    J Inherit Metab Dis; 2018 Nov 07; 41(6):1235-1246. PubMed ID: 29978271
    [Abstract] [Full Text] [Related]

  • 36. Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles.
    Rigon L, Salvalaio M, Pederzoli F, Legnini E, Duskey JT, D'Avanzo F, De Filippis C, Ruozi B, Marin O, Vandelli MA, Ottonelli I, Scarpa M, Tosi G, Tomanin R.
    Int J Mol Sci; 2019 Apr 24; 20(8):. PubMed ID: 31022913
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Evidence and recommendation for mucopolysaccharidosis type II newborn screening in the United States.
    Ream MA, Lam WKK, Grosse SD, Ojodu J, Jones E, Prosser LA, Rosé AM, Comeau AM, Tanksley S, Powell CM, Kemper AR.
    Genet Med; 2023 Feb 24; 25(2):100330. PubMed ID: 36445366
    [Abstract] [Full Text] [Related]

  • 39. Expanding the phenotype of mucopolysaccharidosis type II retinopathy.
    Kowalski T, Ruddle JB, de Jong G, Mack HG.
    Ophthalmic Genet; 2021 Oct 24; 42(5):631-636. PubMed ID: 34251974
    [Abstract] [Full Text] [Related]

  • 40. Lentiviral Gene Therapy for Mucopolysaccharidosis II with Tagged Iduronate 2-Sulfatase Prevents Life-Threatening Pathology in Peripheral Tissues But Fails to Correct Cartilage.
    Catalano F, Vlaar EC, Dammou Z, Katsavelis D, Huizer TF, Zundo G, Hoogeveen-Westerveld M, Oussoren E, van den Hout HJMP, Schaaf G, Pike-Overzet K, Staal FJT, van der Ploeg AT, Pijnappel WWMP.
    Hum Gene Ther; 2024 Apr 24; 35(7-8):256-268. PubMed ID: 38085235
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.